Cellular immunotherapies, including chimeric antigen receptor (CAR)-engineered immune cells, are transforming cancer treatment. As next-generation CAR cell therapies advance toward clinical application, developers require robust methods to evaluate not only target recognition but also receptor expression, binding kinetics, and signaling behavior to optimize reproducibility and therapeutic performance.
The development of effective CAR-NK cell therapies extends beyond selecting an appropriate target antigen. CAR expression levels and ligand-binding kinetics, especially receptor residence times, can substantially influence cellular activity and therapeutic efficacy. In this webinar, we will discuss established approaches for CAR cell characterization, including cytotoxicity assays, activation marker analysis, and flow cytometric assessment of CAR expression. We will then introduce single-cell Interaction Cytometry (scIC), an innovative technology that measures real-time ligand association and dissociation kinetics directly on individual cells. Using a panel of AML-targeting CAR-NK cell lines, we will compare traditional characterization methods with kinetic measurements and demonstrate how these data can support more informed cell therapy development.
DATE
Wednesday, November 25, 2026
11 AM EST | 5 PM CET
Participants will learn how kinetic measurements on living cells complement conventional CAR characterization workflows. Through real measurement examples, we will demonstrate how scIC reveals ligand binding dynamics, quantifies CAR expression, and supports the design of more reproducible and biologically meaningful flow cytometry experiments.
This webinar is intended for cell therapy researchers, immunologists, cell biologists, flow cytometry specialists, and biophysicists interested in cell engineering and beyond. It is particularly relevant for scientists seeking quantitative insight through kinetic measurements performed directly in the native cellular environment.
Charlotte Carcopino
4th year PhD student in the group of Sebastian Kobold at LMU Klinikum.
She is a pharmacist with a master degree in Pharmaceutical Biotechnology from Paris-Saclay University. Currently in her final year of PhD at LMU Munich in Prof. Sebastian Kobold’s lab, her research focuses on developing a universal immunotherapy using CAR engineered-Natural Killer cell for Acute Myeloid Leukemia.
Dr. Nena Matscheko
Teamlead R&D Cells & Antibodies, Bruker Dynamic Biosensors
Nena studied Molecular Biology at the University of Vienna and Biochemistry at the Max Planck Institute in Munich. She joined Dynamic Biosensors more than eight years ago, starting as an Application Specialist and later leading the DNA binder team, where she worked on switchSENSE and complex enzymatic assays. She then moved into technology development, leading a team focused on establishing a new approach for kinetic measurements on cells, now known as scIC.